Indaptus Therapeutics, Inc. 8-K

What Happened
Indaptus Therapeutics, Inc. announced on April 23, 2026 (via Form 8-K) that its Board appointed Tim Ruan and Dr. Yi (Johnny) Zhang as independent directors, effective April 22, 2026. The Board named Mr. Ruan to the Audit Committee (and designated him an “audit committee financial expert”) and Dr. Zhang to the Nominating Committee. Also on April 22, 2026, director Matthew McMurdo resigned; the company said his resignation was not due to any disagreement with the company.

Key Details

• Appointments effective April 22, 2026: Tim Ruan (age 40) and Dr. Yi Zhang (age 48) as independent, Class II directors; their terms expire at the 2026 annual meeting.
• Compensation and protections: each new director will receive a $30,000 annual cash retainer (paid quarterly) and will be covered by an indemnification agreement to the fullest extent permitted by Delaware law.
• Committee roles: Ruan joins the Audit Committee and is an audit committee financial expert under Regulation S-K; Zhang joins the Nominating Committee.
• Backgrounds: Ruan is a seasoned financial executive (current CFO of Ocumension Therapeutics; former roles at Goldman Sachs and Morgan Stanley); Zhang is a life-sciences/IP lawyer and registered U.S. patent attorney with a Ph.D. and a J.D.

Why It Matters
Board composition affects oversight of strategy, finance, compliance and intellectual property—areas important to biotech investors. Adding a CFO-level finance executive with audit committee expertise may strengthen financial oversight and investor relations. Appointing an IP-focused director can help guide patent and freedom-to-operate strategy. The $30,000 retainer and indemnification are standard director protections and compensation items disclosed for investor transparency.